Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | F13A1 | P00488 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | TGM1 | P22735 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CCR6 | P51684 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25787612 | 0.86 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1LMNAMAPT | |
| SCHEMBL16306384 | 0.85 | ALDH1A1 (0.46) | ALDH1A1MAPK1L3MBTL1ALOX5LTA4H | |
| SCHEMBL5577016 | 0.84 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1ALOX5LMNA | |
| SCHEMBL21995358 | 0.84 | ALDH1A1 (0.42) | ALDH1A1MAPK1L3MBTL1ALOX5LMNA | |
| SCHEMBL25252134 | 0.83 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1LMNAMAPT | |
| Hydrochloric Acid SCHEMBL4310487 | 0.83 | LTA4H (0.53) | ALDH1A1MAPK1L3MBTL1ALOX5LMNA | |
| SCHEMBL25211503 | 0.83 | L3MBTL1 (0.48) | ALDH1A1MAPK1L3MBTL1ALOX5LMNA | |
| SCHEMBL390750 | 0.82 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1LTA4HMAPT | |
| SCHEMBL1225570 | 0.82 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1ALOX5MAPT | |
| SCHEMBL393422 | 0.82 | HTT (0.52) | ALDH1A1MAPK1L3MBTL1ALOX5LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4566608-A2 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-4440702-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4445900-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-12187753-B2 | Therapeutics compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4445900-A2 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4440702-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240132527-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2024-04-25 | — | — | US | disclosed |
| US-11787825-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787825-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230203069-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023102239-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023102239-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20220106595-A1 | ANTIBACTERIAL ANTISENSE AGENTS | Pedanius Therapeutics Limited (GB) | 2022-04-07 | — | — | US | disclosed |
| EP-3887520-A1 | ANTIBACTERIAL ANTISENSE AGENTS | Pedanius Therapeutics Limited (GB) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020109792-A1 | ANTIBACTERIAL ANTISENSE AGENTS | Pedanius Therapeutics Limited (GB) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | CD4, HAVCR2, MAVS | ALDH1A1 1512/4885MAPK1 4303/4885L3MBTL1 1204/4885 |
| US-11787825-B2 | Therapeutic compounds for HIV virus infection | HAVCR2, MAVS, CD4 | ALDH1A1 1718/4885MAPK1 4199/4885L3MBTL1 1303/4885 |
| US-12187753-B2 | Therapeutics compounds for HIV virus infection | CD4, HAVCR2, MAVS | ALDH1A1 1512/4885MAPK1 4303/4885L3MBTL1 1204/4885 |
| US-20220106595-A1 | ANTIBACTERIAL ANTISENSE AGENTS | SLC47A1, SLC47A2, ZFR | ALDH1A1 4038/4885MAPK1 3559/4885L3MBTL1 884/4885 |
| US-20230203069-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | HAVCR2, MAVS, CD4 | ALDH1A1 1718/4885MAPK1 4199/4885L3MBTL1 1303/4885 |
| US-20240132527-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | CD4, HAVCR2, MAVS | ALDH1A1 1512/4885MAPK1 4303/4885L3MBTL1 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.